AlphAIalphai — Financial news for AI agents
finance.yahoo.comMAY 275 min read$COLL

Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio

Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 2026 results on May 7, with revenue up 9% YoY to $193.5 million, beating the Street’s $187.4 million estimate. Adjusted EPS rose to $1.76 from $1.49 and topped expectations of $1.63. The company cited strong ADHD franchise growth, including Jornay PM sales up 36% YoY, and expects Jornay PM revenue of $190–$200 million in 2026. Collegium also plans to expand its ADHD portfolio via Azstarys acquisition, expecting it to add over $50 million to H2 2

Original reporting
finance.yahoo.com
Published May 27, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$COLLBullishHigh
01

Why it matters

Q1 outperformance plus explicit 2026 revenue expectations for Jornay PM and expected H2 2026 revenue from Azstarys create a clear catalyst chain for re-rating growth prospects.

02

Market read

A fundamentals catalyst (earnings beat) combined with product-level growth metrics and forward revenue contribution expectations for ADHD drugs.

03

What to watch

The piece doesn’t address competitive intensity, payer restrictions, or execution risks in scaling subscriber base and patient awareness for Jornay PM/Azstarys.

Relevance 9/10Timing: Q1 2026 results (reported May 7) with forward-looking 2026 revenue targets and H2 2026 Azstarys contribution.

Background

The article frames Collegium as gaining attention due to strong ADHD franchise performance and a planned expansion of its ADHD portfolio via Azstarys.

Company-level read

Ticker impact

$COLLBullishHigh confidence
Context

Collegium reported Q1 2026 results that beat Street expectations and highlighted strong ADHD growth in Jornay PM plus Azstarys expansion plans.

Expected impact

Near-term upside bias as investors re-rate the ADHD growth trajectory and H2 2026 revenue contribution from Azstarys.

Evidence & confidence

The article cites Q1 revenue/EPS beats, 36% YoY Jornay PM sales growth, and a specific H2 2026 revenue contribution expectation (> $50M) tied to Azstarys.

Market effects

Sector

Reinforces bullish read-through for ADHD specialty pharma demand, prescriptions, and prescriber expansion dynamics.

Regional

Limited—company-specific catalyst centered on Massachusetts-based Collegium’s product pipeline and commercial execution.

Global

Moderate—ADHD therapeutics demand signals can influence sentiment across specialty pharma, though the article is US-focused.

Counterpoint

What could challenge this read

Azstarys contribution depends on continued prescription/prescriber momentum; any slowdown could pressure the implied 2026 growth path.

Key entities

  • company
    Collegium Pharmaceutical Inc.

    Reported Q1 2026 results that beat expectations; highlighted Jornay PM growth and Azstarys expansion with >$50M H2 2026 revenue expectation.

  • product
    Jornay PM

    ADHD medicine whose sales jumped 36% YoY in Q1, supporting management’s 2026 growth outlook.

  • product
    Azstarys

    ADHD portfolio expansion; expected to contribute more than $50M to H2 2026 revenue per management.

Read at source← All news

Related articles

AUG 6
$COLLHighAI 9/10

Why is Collegium Pharmaceutical stock tumbling today?

Collegium Pharmaceutical shares fell about 13% in pre-open trading after it reported Q2 2026 results and cut full-year revenue guidance. Net revenues were $199.9M, up 6.3% but below analysts’ ~$201.2M-$201.4M. Adjusted EPS was $1.92 and adjusted EBITDA $113.8M. The pain portfolio faced generic competition, while JORNAY PM rose 41% to $46.1M and AZSTARYS added $12.9M.

investing.com4 min
AUG 6
$COLLHigh

COLLEGIUM PHARMACEUTICAL, INC (COLL): Results of Operations and Financial Condition

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 coll-2026x06x30xex99x1.htm EX-99.1 Document Exhibit 99.1 Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress – Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Gener

SEC EDGAR 8-K7 min
AUG 8
$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

yahoo.com6 min
AUG 8
$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

yahoo.com6 min
AUG 8
$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

yahoo.com6 min